Veracyte Secures Medicare Reimbursement for Prosigna Breast Cancer Test
Veracyte said Medicare reimbursement has been secured for its Prosigna test, which assesses breast cancer recurrence risk.
Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancerSOUTH SAN FRANCISCO, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. NASDAQ:VCYT, a leading cancer diagnostics company, today announced that its Prosigna® Breast Risk of Recu…